Could less radiation be just as good for nasopharyngeal cancer?
NCT ID NCT07201337
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 40 times
Summary
This phase 3 trial is testing whether giving a lower dose of radiation to low-risk areas around the main tumor works as well as the standard higher dose for nasopharyngeal cancer. The study plans to enroll 700 people aged 18-70 with newly diagnosed, non-spreading cancer. The goal is to see if the reduced dose can control the cancer just as well while causing fewer side effects and improving quality of life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CANCINOMA (NPC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Affiliated Cancer Hospital of Shantou University Medical College
RECRUITINGShantou, Guangdong, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Affiliated Hospital of Guangdong Medical University
RECRUITINGZhanjiang, Guangdong, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center
RECRUITINGShenzhen, Guangdong, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Dongguan People's Hospital
RECRUITINGDongguan, Guangdong, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Sun yat-sen university cancer center
RECRUITINGGuangzhou, Guangdong, 510060, China
Contact Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The University of Hong Kong-Shenzhen Hospital
RECRUITINGShenzhen, Guangdong, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
radiation therapy
What this could lead to
If successful, this could allow doctors to use lower radiation doses for some patients, reducing long-term side effects while still controlling the cancer.
What could go wrong
This is a large phase 3 trial, but it's testing a non-inferiority approach—meaning the reduced dose might not be as effective as the standard. Results may not apply to all patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.